Results of CTs of curcumin
| CT phase | Evaluated parameters | Patient groups (placebo/control) | Results | References |
|---|---|---|---|---|
| Not specified | Clinical symptoms, O2 saturation, general analysis blood, C-reactive protein (CRP), CT | 24/24 | Decrease in overall Wisconsin Questionnaire score. Level differentiation, high-sensitivity CRP levels, and the degree of lung damage on CT were not different between the two groups. | [93] |
| 3 | Levels of serum secretion of inflammatory cytokines IL-1β, IL-6, and TNF-α | 30/30 | Curcumin can significantly increase the frequency and function natural killer cells compared to the group that received a placebo. | [94] |
| 3 | Symptoms (fever, chills, myalgia, cough), O2 saturation | 21/20 | Reduced hospitalization time, O2 saturation was significantly higher in the group treatment. | [95] |
| Not specified | Clinical signs and gene expression of T-box transcription factor 21, GATA binding protein 3, RAR-related orphan receptor C, and forkhead box P3, serum levels of cytokines interferons-γ (IFN-γ), IL-4, IL-17, and transforming growth factor beta | 20/20 | Serum levels of IFN-γ and IL-17 decreased, and IL-4 and transforming growth factor beta increased in the curcumin group compared with the placebo. TBX21 and FOXP3 gene expression was significantly reduced. | [96] |
| 3 | Clinical signs and mRNA of IFN-γ, IL-1β, IL-6, monocyte chemoattractant protein-1, and TNF-α and levels of the inflammatory mediators IL-1β, IL-6, and TNF-α in serum | 30/30 | Clinical manifestations and laboratory parameters improved after curcumin treatment, IFN-γ and TNF-α mRNA expression decreased significantly. There was a significant difference between curcumin and the control group in the expression of IFN-γ, IL-1β, and IL-6; and a significant difference between curcumin and controls in serum levels of IL-1β. | [97] |
| Not studied | Clinical symptoms, O2 saturation | 70/70 | Patients with moderate and severe symptoms who received curcumin treatment showed an earlier recovery compared to patients in the control group. Curcumin treatment shortened the duration of hospitalization in patients with moderate to severe symptoms; the curcumin treatment group had fewer deaths. | [99] |
